Predictors and biomarkers of pain in newly diagnosed Parkinson?s disease patients during a two-year follow-up

PEREZ LLORET S; SAUERBIER A; FALUP-PECURIARU C; KR CHAUDHURI

Hong Kong

Congreso; 22th International Congress of Parkinson?s Disease and Movement Disorders; 2018

International Parkinson and Movement Disorders Society

OBJECTIVE: To identify clinical characteristics, predictors and biomarkers of pain at baseline and after a two-year follow-up period in newly diagnosed drug-naïve PD patients enrolled in the Parkinson?s Progression Markers Initiative (PPMI) database.BACKGROUND: Pain is a frequent and sometimes disabling non-motor symptom of Parkinson?s disease (PD).METHODS: The PPMI is a cohort study aimed at identifying clinical, imaging and biologic markers of PD progression. For this sub-study, 422 newly diagnosed drug-naïve PD patients and 195 healthy controls were included. Patients were assessed by means of the MDS-UPDRS, MoCA, SCOPA, ESS, RBD Screening Questionnaire, GDS-15, STAI, and UPSIT. DAT imaging was used to assess dopaminergic loss. Levels of β-amyloid fragment 1-42, α-synuclein and total or phosphorylated tau proteins were measured in cerebrospinal fluid (CSF). The main outcome was pain, defined as MDS-UPDRS item 1.9 (pain and other sensations) ≥ 1.RESULTS: Pain prevalence at baseline was higher in PD (n=221/422, 52%) compared to healthy controls (n=65/195, 33%, p